Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus B19 infection: A retrospective study of 10 patients and review of the literature

Clinical Infectious Diseases

Volumn 56, Issue 7, 2013, Pages 968-977

  Crabol, Yoann ^a   Terrier, Benjamin ^a   Rozenberg, Flore ^a   Pestre, Vincent ^a   Legendre, Christophe ^a   Hermine, Olivier ^a   Montagnier Petrissans, Catherine ^b   Guillevin, Loïc ^a   Mouthon, Luc ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Human parvovirus B19; IgG; Infection; Intravenous immunoglobulin; Pure red cell aplasia

Indexed keywords

COBALAMIN; CORTICOSTEROID; ERYTHROPOIETIN; FOLIC ACID; HEMOGLOBIN; IMMUNOGLOBULIN;

ADOLESCENT; ADULT; AGED; ARTHRALGIA; BLOOD TRANSFUSION; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG TOLERANCE; FEMALE; HEADACHE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMOGLOBIN BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN PARVOVIRUS B19; IMMUNOCOMPROMISED PATIENT; KIDNEY FAILURE; LOW DRUG DOSE; LUNG EDEMA; MALE; MEDICAL HISTORY; MYALGIA; MYELODYSPLASTIC SYNDROME; ONSET AGE; PARVOVIRUS INFECTION; PRIORITY JOURNAL; PURE RED CELL ANEMIA; RELAPSE; RETICULOCYTE COUNT; RETROSPECTIVE STUDY; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY; MALE; MIDDLE AGED; PARIS; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; RED-CELL APLASIA, PURE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84875048557     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis1046     Document Type: Review

References (31)

1. Yoshida Y. Historical review. The light and shadow of Paul Kaznelson: his life and contribution to hematology. Ann Hematol 2008; 87: 877-9.
2. Ammus SS, Yunis AA. Acquired pure red cell aplasia. Am J Hematol 1987; 24: 311-26.
3. Brown KE, Young NS. Parvovirus B19 infection and hematopoiesis. Blood Rev 1995; 9: 176-82.
4. Röhrer C, Gärtner B, Sauerbrei A, et al. Seroprevalence of parvovirus B19 in the German population. Epidemiol Infect 2008; 136: 1564-75.
5. Kurtzman G, Frickhofen N, Kimball J, Jenkins DW, Nienhuis AW, Young NS. Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med 1989; 321: 519-23.
6. Mouthon L, Guillevin L, Tellier Z. Intravenous immunoglobulins in autoimmune- or parvovirus B19-mediated pure red-cell aplasia. Autoimmun Rev 2005; 4: 264-9.
7. Koduri PR, Kumapley R, Khokha ND, Patel AR. Red cell aplasia caused by parvovirus B19 in AIDS: use of i.v. immunoglobulin. Ann Hematol 1997; 75: 67-8.
8. Koduri PR, Kumapley R, Valladares J, Teter C. Chronic pure red cell aplasia caused by parvovirus B19 in AIDS: use of intravenous immunoglobulin- a report of eight patients. Am J Hematol 1999; 61: 16-20.
9. Kondo H, Mori A, Watanabe J, Takada J, Takahashi Y, Iwasaki H. Pure red cell aplasia associated with parvovirus B19 infection in T-large granular lymphocyte leukemia. Leuk Lymphoma 2001; 42: 1439-43.
10. Amiot L, Langanay T, Drénou B, et al. Spontaneous recovery from severe parvovirus B19 pure red cell aplasia, in a heart transplant recipient, as demonstrated by marrow culture. Hematol Cell Ther 1998; 40: 71-3.
11. Wong TY, Chan PK, Leung CB, Szeto CC, Tam JS, Li PK. Parvovirus B19 infection causing red cell aplasia in renal transplantation on tacrolimus. Am J Kidney Dis 1999; 34: 1132-6.
12. Geetha D, Zachary JB, Baldado HM, Kronz JD, Kraus ES. Pure red cell aplasia caused by parvovirus B19 infection in solid organ transplant recipients: a case report and review of literature. Clin Transplant 2000; 14: 586-91.
13. Cavallo R, Merlino C, Re D, et al. B19 virus infection in renal transplant recipients. J Clin Virol 2003; 26: 361-8.
14. Chernak E, Dubin G, Henry D, et al. Infection due to parvovirus B19 in patients infected with human immunodeficiency virus. Clin Infect Dis 1995; 20: 170-3.
15. Eid AJ, Brown RA, Patel R, Razonable RR. Parvovirus B19 infection after transplantation: a review of 98 cases. Clin Infect Dis 2006; 43: 40-8.
16. Erdman DD, Usher MJ, Tsou C, et al. Human parvovirus B19 specific IgG, IgA, and IgM antibodies and DNA in serum specimens from persons with erythema infectiosum. J Med Virol 1991; 35: 110-115.
17. Yango A Jr, Morrissey P, Gohh R, Wahbeh A. Donor-transmitted parvovirus infection in a kidney transplant recipient presenting as pancytopenia and allograft dysfunction. Transpl Infect Dis 2002; 4: 163-6.
18. Marchand S, Tchernia G, Hiesse C, et al. Human parvovirus B19 infection in organ transplant recipients. Clin Transplant 1999; 13: 17-24.
19. Viguier M, Guillevin L, Laroche L. Treatment of parvovirus B19- associated polyarteritis nodosa with intravenous immune globulin. N Engl J Med 2001; 344: 1481-2.
20. Kumar J, Shaver MJ, Abul-Ezz S. Long-term remission of recurrent parvovirus-B associated anemia in a renal transplant recipient induced by treatment with immunoglobulin and positive seroconversion. Transpl Infect Dis 2005; 7: 30-3.
21. Morelli P, Bestetti G, Longhi E, Parravicini C, Corbellino M, Meroni L. Persistent parvovirus B19-induced anemia in an HIV-infected patient under HAART. Case report and review of literature. Eur J Clin Microbiol Infect Dis 2007; 26: 833-7.
22. Wasak-Szulkowska E, Grabarczyk P, Rzepecki P. Pure red cell aplasia due to parvovirus B19 infection transmitted probably through hematopoietic stem cell transplantation. Transpl Infect Dis 2008; 10: 201-5.
23. Uemura N, Ozawa K, Tani K, et al. Pure red cell aplasia caused by parvovirus B19 infection in a renal transplant recipient. Eur J Haematol 1995; 54: 68-9.
24. Mylonakis E, Dickinson BP, Mileno MD, et al. Persistent parvovirus B19 related anemia of seven years' duration in an HIV-infected patient: complete remission associated with highly active antiretroviral therapy. Am J Hematol 1999; 60: 164-6.
25. Arribas JR, Peña JM, Echevarría JE. Parvovirus B19-related anemia in an HIV-infected patient: rapid control after production of neutralizing antibodies during highly active antiretroviral therapy. Ann Intern Med 2000; 132: 1011.
26. Nolan RC, Chidlow G, French MA. Parvovirus B19 encephalitis presenting as immune restoration disease after highly active antiretroviral therapy for human immunodeficiency virus infection. Clin Infect Dis 2003; 36: 1191-4.
27. Ito S, Oyake T, Uchiyama T, Sugawara T, Murai K, Ishida Y. Successful treatment with cyclosporine and high-dose gamma immunoglobulin for persistent parvovirus B19 infection in a patient with refractory autoimmune hemolytic anemia. Int J Hematol 2004; 80: 250-3.
28. Sturm I, Watschinger B, Geissler K, et al. Chronic parvovirus B19 infection- associated pure red cell anaemia in a kidney transplant recipient. Nephrol Dial Transplant 1996; 11: 1367-70.
29. Ramage JK, Hale A, Gane E, et al. Parvovirus B19-induced red cell aplasia treated with plasmapheresis and immunoglobulin. Lancet 1994; 343: 667-8.
30. Fakhouri F. Intravenous immunoglobulins and acute renal failure: mechanism and prevention [in French]. Rev Med Interne 2007; May 28(Spec No. 1): 4-6.
31. Renal insufficiency and failure associated with immune globulin intravenous therapy - United States, 1985-1998. MMWR Morb Mortal Wkly Rep 1999; 48: 518-21.